Influenza vaccination in 2026: a new era of protection

A Shifting Landscape for Flu Protection

Influenza continues to impose a heavy annual toll, with seasonal epidemics causing hundreds of thousands of hospitalizations and deaths globally each year, disproportionately affecting older adults, young children, and those with underlying conditions. Recent patterns have intensified concern: unusually high out-of-season cases have appeared in both the northern and southern hemispheres, straining health systems already dealing with variable vaccine uptake.

In Australia, authorities have flagged 2026 as a critical year for boosting immunization rates to protect vulnerable populations from serious illness and hospital admissions. A notable change is the first-time availability and funding of the live attenuated influenza vaccine (LAIV) through certain state and territory programs, expanding options beyond traditional injectable vaccines.

Globally, the most striking development is the push toward next-generation technologies. Moderna's mRNA-1010 candidate, which uses the same platform as its COVID-19 vaccine, has advanced to regulatory scrutiny in multiple jurisdictions including the US, Europe, Canada, and Australia. The FDA initially issued a refusal-to-file letter in early February 2026 citing trial design concerns but reversed course within days after discussions, accepting a revised application with full approval sought for ages 50-64 and accelerated approval for those 65 and older, contingent on post-market studies. A decision is expected by August 5, 2026, potentially enabling availability for the 2026-2027 season.

This comes amid broader momentum for improved vaccines. The WHO has highlighted how next-generation options could avert billions of cases and millions of deaths over the coming decades, while also reducing antibiotic use. Yet progress on truly universal vaccines—offering broad, long-lasting protection against diverse strains—remains in clinical stages, with dozens of candidates but no imminent approvals.

Tensions persist beneath the surface. mRNA technology promises quicker adaptation to circulating strains and faster scaling during pandemics, advantages not fully captured in single-season data. However, recent regulatory volatility has prompted warnings that unpredictable US policies could push innovation abroad, weakening domestic preparedness. Meanwhile, incremental improvements from mRNA or recombinant vaccines face scrutiny over cost, side-effect profiles, and whether they outperform existing high-dose or adjuvanted options enough to shift public health recommendations substantially.